La catena delle opzioni mostra i dati chiave delle opzioni azionarie di 10x Genomics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per 10x Genomics..

10x Genomics (NASDAQ:TXG) Azioni, Catena delle Opzioni

10X GENOMICS INC-CLASS A

10x Genomics

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

Russia,Moscow,24.06.2021,Logo,Of,Financial,Investing,Fund,Ark,Invest

Equities

News

Markets

ETFs

ARKK

ARKW

ARKX

CRSP

KTOS

PACB

PLTR

SHOP

Movimenti sui fondi ETF della nota investitrice. Cessioni del titolo AI, acquisti mirati su chip ed e-commerce. Attività anche su biotech.

Cathie Wood vende Palantir prima degli utili e acquista questi 2 titoli

Stuttgart,,Germany,-,03-11-2021:,Person,Holding,Cellphone,With,Company,Logo

ADPT

ARKQ

NRIX

NVDA

PATH

Nuovi acquisti per il fondo guidato dalla celebre investitrice, focus su un settore chiave. Ribilanciamento in corso nel portafoglio.

Cathie Wood non si ferma più: Ark Invest compra ancora questi titoli

10x Genomics Inc

TEXAS GULF ENERGY INC by Texas Gulf Energy, Incorporated.

Texas Gulf Energy Inc

Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) may be gearing up for a significant rally, with analysts pointing to $0.30 as the next major resistance if the meme coin can hold <a href="https://www.benzinga.com/money/dogecoin-doge-price-prediction">current support levels</a>.
What Happened: Trader Altcoin Sherpa noted that DOGE recently broke out after two months of sideways trading. 
Unlike similar setups in late 2024, this move is underpinned by macro and election catalysts. 
He emphasized that the next few weeks are crucial:
<ul class="wp-block-list">
<li>If DOGE holds current levels, he expects a push to $0.30.</li>
<li>If support fails, a drop to $0.15 is likely.</li>
</ul>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24DOGE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$DOGE</a> has an interesting chart. It chopped for about 2 months or so recently and had a strong move; tbd if this is going to come back down. Prob not comparable to previous consolidations in late 2024 due to election + other macro factors. Still, we&#39;re about to see if it creates a… <a href="https://t.co/Qib0AP5lLB">pic.twitter.com/Qib0AP5lLB</a>
&mdash; Altcoin Sherpa (@AltcoinSherpa) <a href="https://twitter.com/AltcoinSherpa/status/1924784091280638343?ref_src=twsrc%5Etfw">May 20, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Crypto General <a href="https://x.com/dacryptogeneral/status/1924493125654827170?s=46">added</a> that Dogecoin's breakout appears strong but expects a retest of the trendline before launching a larger rally. His entry plan is on the retest, targeting $0.30.
Trader Tardigrade <a href="https://x.com/tatrader_alan/status/1924732876610056502?s=46">highlighted </a>DOGE's current consolidation just below resistance, forming a textbook breakout structure. He expects the price to test resistance multiple times before breaking through, setting his next target at $0.40.
On the bearish side, Ali Martinez <a href="https://x.com/ali_charts/status/1924744403803111518?s=46">warned</a> of a potential pullback to $0.213, citing technical signals that suggest the price may revisit a key support zone before any further upside.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45448145/dogecoin-down-1-but-this-pattern-signals-a-breakout-is-imminent">Dogecoin Down 1% But This Pattern Signals A Breakout Is Imminent</a>
Why It Matters: Coinglass data shows Dogecoin open interest increased by 1.7% to $2.6 billion in a single day. 
Liquidation sin the past 24 hours stood at $6.14 million, with $4.07 million in long liquidations.
Glassnode data shows Dogecoin active addresses up from 61,892 on May 7 to 674,527 as of May 14, implying a 990% spike in a week. 
DOGE futures open interest surged more than 66% over the past week to $1.65 billion.
Coinbase <a href="https://x.com/CoinbaseAssets/status/1922387735580450838">announced</a> that wrapped Dogecoin (cbDOGE) will launch on the Base network, its Layer-2 Ethereum scaling solution. This could unlock new institutional and DeFi integrations, further boosting DOGE&#8217;s ecosystem appeal.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45474296/dogecoin-up-47-in-one-month-how-much-higher-can-it-go">Dogecoin Up 47% In One Month: How Much Higher Can It Go?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

Is A Dogecoin Breakout To $0.30 Brewing?

U.S. stocks were lower, with the Nasdaq Composite falling more than 50 points on Tuesday.
Shares of Agilysys, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGYS#NASDAQ">AGYS</a>) rose sharply during Tuesday's session following <a href="https://in.benzinga.com/news/earnings/25/05/45506384/agilysys-reports-better-than-expected-q4-earnings-shares-move-higher-after-hours">better-than-expected fourth-quarter results.</a>
Agilysys reported fourth-quarter revenue of $74.27 million, beating analyst estimates of $71.42 million, according to Benzinga Pro. The hospitality software provider reported fourth-quarter earnings of 54 cents per share, beating estimates of 29 cents per share.
Agilysys shares jumped 18.6% to $98.50 on Tuesday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>D-Wave Quantum Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) shares jumped 26% to $16.59 after the company announced it launched its Advantage2 quantum system to address problems in optimization, AI, and materials simulation.</li>
<li>Mind Medicine (MindMed) Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNMD#NASDAQ">MNMD</a>) shares rose 17.1% to $8.21. MindMed announced new employee inducement grants.</li>
<li>Amer Sports, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AS#NYSE">AS</a>) jumped 16.6% to $36.62 after the company reported better-than-expected first-quarter financial results and raised its FY25 guidance.</li>
<li>X Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYF#NYSE">XYF</a>) gained 15.8% to $17.38 after the company reported a year-over-year increase in first-quarter financial results.</li>
<li>COMPASS Pathways plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) rose 14.9% to $4.9999.</li>
<li>Syndax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) gained 11% to $10.32.</li>
<li>GIBO Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIBO#NASDAQ">GIBO</a>) rose 10.4% to $3.50.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) gained 9.6% to $385.35.</li>
<li>Sasol Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSL#NYSE">SSL</a>) rose 8.5% to $4.45.</li>
<li>Sibanye Stillwater Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBSW#NYSE">SBSW</a>) gained 8.5% to $5.26.</li>
<li>Magnite, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>) shares rose 6.3% to $16.29. Amazon Publisher Services (APS) and Magnite announced a deeper streaming TV collaboration through APS&#8217; Transparent Ad Marketplace (TAM) and Magnite&#8217;s SpringServe.</li>
<li>Pegasystems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) gained 5.3% to $103.64 following announcements that the company will join the S&amp;P Midcap 400. </li>
</ul>
Now Read This:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/news/earnings/25/05/45511338/home-depot-toll-brothers-and-3-stocks-to-watch-heading-into-tuesday">Home Depot, Toll Brothers And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

Movers

Trading Ideas

AGYS

CMPS

GIBO

MGNI

MNMD

PEGA

QBTS

SBSW

SNDX

Agilysys, Amer Sports, X Financial And Other Big Stocks Moving Higher On Tuesday

CIBC analyst Kevin Chiang maintains TFI International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFII#NYSE">TFII</a>) with a Outperformer and raises the price target from $110 to $118.

Price Target

Analyst Ratings

TFII

CIBC Maintains Outperformer on TFI International, Raises Price Target to $118

WIIM

ATAI

ATAI Life Sciences shares are trading higher after the company announced topline data from part 2 of its Phase 2a study of BPL-003.

TRNS

Transcat shares are trading higher following better-than-expected Q4 financial results.

RBC Capital analyst Walter Spracklin upgrades Westshore Terminals (TSX:<a class="ticker" href="https://www.benzinga.com/stock/WTE#TSX">WTE</a>) from Sector Perform to Outperform and raises the price target from C$23 to C$30.

Upgrades

TSX:WTE

RBC Capital Upgrades Westshore Terminals to Outperform, Raises Price Target to C$30

Mind Medicine and Compass Pathways shares are trading higher on possible continued strength amid a report on Monday from the FDA commissioner stating the exploration of psychedelic medicine is a top priority.

Truist Securities analyst Michael Lewis maintains Piedmont Office Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PDM#NYSE">PDM</a>) with a Buy and lowers the price target from $10 to $9.

Truist Securities Maintains Buy on Piedmont Office Realty, Lowers Price Target to $9

TRML

Tourmaline Bio shares are trading lower. The company announced topline results from its ongoing Phase 2 TRANQUILITY trial.

PRPH

PRPH stock has given up its prior gain. ProPhase Labs shares were trading higher after the company reported a Q1 EPS beat.

ASPI

ASPI stock has given up its prior gain. ASP Isotopes shares were trading higher after announcing it has entered into a loan and supply agreement with TerraPower for a new HALEU uranium enrichment facility in South Africa.

Stifel analyst Tore Svanberg maintains Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) with a Buy and raises the price target from $225 to $248.

Stifel Maintains Buy on Analog Devices, Raises Price Target to $248

To say that early 2025 has been difficult for Tesla (NASDAQ:<a href="https://www.benzinga.com/quote/TSLA"> TSLA</a>) stockholders would be an understatement. Company profits and sales figures are way down, and many attribute this to the growing unpopularity of CEO Elon Musk.&nbsp; Despite that, Morgan Stanley analysts are bullish about the company's long-term outlook. Keep reading to find out why.
Tesla's public fall from grace has been as sudden as it was unexpected. As recently as a year ago, the business world hailed Musk as everything from an innovator to a genius. Tesla cars were almost unchallenged as America's favorite EV, and the future looked even brighter. The bottom began falling out shortly after Musk took on a leadership role at DOGE.
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.30/share!</a></li>
</ul>
Then there was his open embrace of Germany's far-right AFD political party. It all combined to create the perfect storm of unpopularity.<a href="https://www.benzinga.com/25/05/45376757/tesla-back-in-the-trillionaire-club-tsla-stock-roars-back-with-40-rebound-robotaxi-mania"> Tesla</a> sales plummeted in the U.S. and Europe despite rising demand for EVs. The stock tanked, and things got so bad that there were rumors that Tesla's board was quietly searching for a new CEO. That seems like a rather odd backstory for a stock that Morgan Stanley Analyst Adam Jonas rated as a "top pick."
To be certain, Jonas is not predicting that disgruntled Tesla customers will come rushing back anytime soon. His prediction is based on other factors, most notably the belief that Tesla is more than just a car company.&nbsp;
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a>
According to<a href="https://www.tipranks.com/news/morgan-stanley-doubles-down-on-tesla-stock"> Tipranks</a>, Jonas is basing his analysis on an acronym that he calls D.R.E.A.M.S. The breakdown is:&nbsp;&nbsp;
<ul class="wp-block-list">
<li> Data: Even with plummeting sales numbers, Tesla has over 7 million vehicles on the road and expects that there will be 40 million by 2040. This creates an avalanche of driver and consumer data for Tesla to manipulate and market</li>
<li>Robotics: Tesla produces cars using its own robots, and this technology will have value beyond just EV production</li>
<li>Energy: Tesla is also a leader in producing electrical batteries that can power operations both large and small</li>
<li>AI: Tesla has an advance AI department that's helping to develop its self-driving cars and will have other valuable uses in the future</li>
<li>Manufacturing: Jonas says Tesla is "the "most vertically integrated, US-local sourced auto company in the world."</li>
<li>Space: Jonas believes Tesla's SpaceX division is the "data transport layer – the connective tissue of the AI ecosystem."</li>
</ul>
Jonas believes this combination of advantages and assets will allow Tesla to survive the current downturn and thrive in the long term. His analysis noted, "We're often asked what is Tesla's secret sauce? What's its moat? Well – it's not really 1 thing but the combination of 6 attributes that set Tesla apart from its peers."
See Also: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
He expanded on this during a<a href="https://www.youtube.com/watch?v=y-h4_TzyBm8"> CNBC interview</a>, saying, "I think Tesla is an overvalued auto company, but an undervalued onshore and renewable energy company. It is time to unleash the arsenal of democracy to control our energy destiny, and we at Morgan Stanley, at least, we struggle to find a name that's better positioned than Tesla to show us the way to do that."
Jonas has given Tesla a rating of Overweight and set a $410 price target. That means he sees Tesla as roughly 20% undervalued. That's a bullish prediction considering Tesla's current circumstances, but he's not alone in his belief that Tesla could reach the $400 per share plateau.<a href="https://www.benzinga.com/markets/equities/25/05/45387982/why-tesla-is-my-top-stock-pick-for-2025-the-year-of-elon-musk-again"> Benzinga</a> compiled<a href="https://www.benzinga.com/quote/TSLA/analyst-ratings"> Tesla target prices</a> from 27 analysts, who have a consensus price expectation of $295.23, but Stifel sees Tesla hitting $450.
Wedbush's most recent guidance from February sees Tesla hitting $475 per share. Jonas's continued belief in Tesla is rooted in the idea that the company's other technologies and capabilities give it viability as something beyond a car company. That means this could be the perfect time for investors to get back on the Tesla train.&nbsp;
Read Next:
<ul class="wp-block-list">
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
Image: Shutterstock

Why Morgan Stanley Remains Bullish On Tesla

Stifel analyst Alex Thompson reinstates Kymera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) with a Buy and announces $55 price target.

Initiation

KYMR

Stifel Reinstates Buy on Kymera Therapeutics, Announces $55 Price Target

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/20062449/Unigroup-0520-900x600-1.png" alt="" class="wp-image-13139" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/20062449/Unigroup-0520-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/20062449/Unigroup-0520-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/20062449/Unigroup-0520-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
Zhao Weiguo, former chairman of the once highflying Tsinghua Unigroup, received a suspended death sentence last week for corruption
Key Takeaways:
<ul class="wp-block-list">
<li>The rise and fall of Zhao Weiguo, who was sentenced to death last week for corruption, is closely intertwined with China's aggressive chip ambitions, and reveals its cracks</li>
<li>The vehicle for Zhao's chip empire, Tsinghua Unigroup, has been restructured after defaulting on its debt and is currently on a less ambitious path</li>
</ul>
A courtroom in a remote city in Northeastern China's Jilin province wouldn't normally attract too much attention, focused mostly on local matters. But a verdict it delivered last week resonated not only in China, but around the world, as the career of a man who once embodied China's aggressive ambitions to build up its microchip industry, came to a quiet end.
The story of Zhao Weiguo, who received a suspended death sentence, is in many ways the story of China's race to catch up with the West in its ability to make microchips that power everything from microwave ovens to supercomputers. But it's also the story of the many problems that have come with that campaign, including its hundreds of billions of dollars in state support.
Zhao, 58, committed embezzlement, abused his power to benefit relatives and friends, and caused significant losses to the state and a listed company while chairman of state-backed&nbsp;Tsinghua Unigroup, according to numerous media reports, citing a verdict from the Jilin Intermediate People's Court.
A photo on the day of the verdict shows a humbled and gaunt Zhao in court, flanked by two policemen — a far cry from the confidence-exuding man whose acquisitions were legendary, including ambitions at one point to buy Taiwan's&nbsp;TSMC, the world's largest and most advanced contract chip maker.
The court found that Zhao used his roles at Unigroup from 2014 to 2021 to steer business and assets to his associates at the expense of the company and state interests. As a result, over 470 million yuan ($65 million) in state assets were illegally obtained, more than 890 million yuan in state losses incurred, and a listed company suffered losses exceeding 46 million yuan. The reality is that those numbers are likely only a fraction of the huge waste and corruption that occurred during Zhao's tenure.
<h4 class="wp-block-heading">Reliant on imports</h4>
China manufactures much of the world's electronics but relies heavily on imported semiconductors chips that form the "brains" of such products. As U.S.-China tensions have intensified in recent years, the country has faced increasing and more coordinated restrictions on importing some of the most advanced technologies, including chips and chip-making equipment. China has long been determined to achieve self-reliance in this area — a campaign often encapsulated by slogans such as "China Chip."
The campaign picked up significant speed in June 2014, when China released a blueprint for developing its semiconductor industry, aiming to reach advanced levels by 2030. Three months later, it established the massive China Integrated Circuit Industry Investment Fund, also known as the "Big Fund," to support companies and projects that could help to achieve its objectives. Now in its third phase, the fund has raised a staggering 680 billion yuan to date and has been marred with corruption and waste.
Zhao Weiguo appeared ideal to lead such ambitions. From his humble beginnings in a small village in Northwestern China's Xinjiang region, he went on to attend Tsinghua University, China's leading sciences institution, in the 1980s.
An electrical engineering student, Zhao said in interviews that he was inspired to become an entrepreneur after reading a book about Silicon Valley and the founding of Apple and Hewlett-Packard. His entrepreneurial spirit led him through ventures in a cement factory, the first wave of China's dot-com boom, and later real estate and infrastructure, before he founded Beijing Jiankun Investment Group in the early 2000s.
In 2009, Zhao, through Jiankun, acquired a significant stake in Tsinghua Unigroup, an entity founded in 1988 to commercialize the university's research. He became chairman of the company a year later.
For years, Unigroup remained an undistinguished state-owned enterprise without any distinct strategies or standout products. Two subsidiaries,&nbsp;Unisplendour&nbsp;and&nbsp;Unigroup Guowei, listed on the Shenzhen Stock Exchange in 1999 and 2007, respectively, but both drew little attention and were largely obscure small caps.
<h4 class="wp-block-heading">In search of acquisitions</h4>
Seeking to raise his company's profile, Zhao began looking for acquisitions, often browsing financial websites in search of targets. One night in late 2012, he spotted&nbsp;Spreadtrum Communications, a Nasdaq-listed Chinese telecoms chipmaker, and ultimately purchased it in 2013 for $1.78 billion. That marked Unigroup's first move into the chip industry, kicking off a years-long acquisition binge targeting big names both in China and abroad.
In 2014, the company acquired Spreadtrum rival&nbsp;RDA Microelectronics, and later merged the two. In 2015, it acquired 51% of&nbsp;Hewlett-Packard's H3C Technologies and the U.S. PC giant's China server, storage, and technology services businesses for about $2.3 billion. In one of its crowning achievements, Unigroup in 2016 founded&nbsp;Yangtze Memory Technologies,&nbsp;now considered China's national champion for memory chips.
A number of its attempts to acquire major international tech firms were blocked as Unigroup's profile rose and the West became wary of letting China acquire its most advanced technologies. The company's attempts to acquire leading U.S. disk drive maker&nbsp;Western Digital&nbsp;and memory chip maker&nbsp;Micron&nbsp;were both blocked by the U.S. in 2015 over national security concerns. Zhao's attempts to buy leading chip packaging and testing companies in Taiwan were also blocked for similar reasons.
The aggressive expansion and failed acquisition attempts quickly made Unigroup China's most influential chip conglomerate. But the campaign also left the company heavily in debt, even as it received significant state funding from various sources, reportedly including 150 billion yuan from China Development Bank and the Big Fund in 2017.
Its debt load soon became unsustainable, as many of its ventures gobbled up cash without yielding big returns. The company defaulted on its first bond in November 2020, by which time it had accumulated more than 200 billion yuan in debt. Unigroup was forced to restructure, and a government-led consortium led by Beijing Zhiguangxin Holding took control in 2022, by which time the company had sold off stakes in both its core and non-core businesses.
Zhao's star was already rapidly fading by that time, and took a final hit when China launched an anti-corruption campaign targeting the sector, which ultimately netted not only himself but also multiple executives from the Big Fund and other chip firms.
Zhao could still emerge from prison in as little as 15 years under his suspended death sentence, which is considered lenient because he confessed his crimes and returned his illegal gains. But Unigroup's huge waste and cost to the state will remain a blemish on China's chip ambitions for far longer, even if it ultimately achieves its aim of making the country into a global semiconductor powerhouse.

Asia

Opinion

Tech

Corruption Case Blemishes China's Chip Ambitions

Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) has outperformed the market over the past 20 years by 2.56% on an annualized basis producing an average annual return of 10.87%. Currently, Charles Schwab has a market capitalization of $162.09 billion. 
Buying $1000 In SCHW: If an investor had bought $1000 of SCHW stock 20 years ago, it would be worth $7,887.71 today based on a price of $89.21 for SCHW at the time of writing.
<h3>Charles Schwab's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747750514_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SCHW

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) may be flirting with all-time highs again and this is not déjà vu from November 2024. BTC's surge back then was turbocharged by sentiment and speculation. This time around, the rally is built on sturdier ground. Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) isn&#8217;t going unnoticed either. <a href="https://www.benzinga.com/crypto">The crypto company went </a>up 40% in a week.
While price action is bullish for both tokens, what's driving their momentum today may be structurally different.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45504098/bitcoin-ethereum-rebound-while-xrp-dogecoin-struggle-105000-remains-critical-resistance">Bitcoin, Ethereum Rebound While XRP, Dogecoin Struggle — $105,000 Remains Critical Resistance</a>
<h2 class="wp-block-heading">Bitcoin: Slower Climb, Stronger Foundation?</h2>
Bitcoin surged from roughly $94,000 in early May 2025 to over $106,000 &#8211; up 13%. While that may seem impressive, James Toledano, chief operating officer at Unity Wallet, says the move "echoes" the November 2024 rally, when BTC spiked nearly 37% in a single month.
"Many of the driving forces appear to be the same," says Toledano, pointing to "rapid price increases and strong institutional interest." However, the current rally is supported by more than just sentiment.
"This ascent is fueled by the cooling tariffs, which has helped ease market chaos, increased ETF inflows, and recent corporate acquisitions like <a href="https://www.benzinga.com/markets/25/05/45510163/el-salvadors-bitcoin-holdings-show-357-million-in-unrealized-profit-as-bitcoin-closes-at-record-high">Metaplanet's purchase of 1,004 BTC</a>," he says. 
Compared to last year's sentiment-driven rally, Toledano sees today's uptrend as "underpinned by tangible institutional adoption and policy support," suggesting it may be more sustainable.
<h2 class="wp-block-heading">Ethereum Up 40% In A Week</h2>
Ethereum's recent 40% surge was catalyzed by a successful network upgrade and improving global macro conditions. But Dom Harz, co-founder of BOB, believes it reflects more profound changes.
"The recent rally in Ethereum's price isn't just about short-term positioning, but rather is a reflection of a deeper shift in the market's understanding of what the future of blockchain infrastructure will look like," says Harz.
He argues the conversation is shifting from siloed chains to hybrid models &#8220;that leverage the best of both worlds: security and liquidity on Bitcoin's side, and battle-tested dApps with proven UX on Ethereum's side."
Per Harz, security remains the core requirement for financial infrastructure. As such, Bitcoin "will become the foundation for the next generation of DeFi."
Ethereum's future depends on "alignment," not competition. "This isn't about allegiance," he concludes. "It's about alignment."
While both Bitcoin and Ethereum are soaring, their convergence through institutional adoption and hybrid infrastructure could define the next phase of crypto—and smart money is betting on that.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45517785/bitcoin-to-hit-500000-by-2028-standard-chartered-says-as-etfs-buy-667m-on-monday">Bitcoin To Hit $500,000 By 2028, Standard Chartered Says, As ETFs Buy $667M On Monday</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Long Ideas

$BTC

$ETH

Bitcoin Vs. Ethereum? Try BTC + ETH - Why Smart Money Bets On Both

RBC Capital analyst Mike Dahl maintains Smith Douglas Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDHC#NYSE">SDHC</a>) with a Sector Perform and lowers the price target from $21 to $16.

SDHC

RBC Capital Maintains Sector Perform on Smith Douglas Homes, Lowers Price Target to $16

Eyenovia Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares surged 38.9% to $1.57 on Tuesday morning after the ophthalmic technology firm announced progress in its planned merger with Betaliq and reported an improved first-quarter financial performance.
What To Know: The company <a href="https://www.benzinga.com/pressreleases/25/05/g45507443/eyenovia-provides-updates-on-potential-merger-with-betaliq-and-development-of-the-optejet-user-fil">extended</a> its exclusive merger negotiation period with Betaliq, a private pharmaceutical firm focused on glaucoma therapies, until June 7, 2025, signaling continued momentum toward a definitive agreement. Eyenovia aims to leverage Betaliq's proprietary Eyesol platform alongside its own FDA-approved Optejet delivery technology.
Separately, the company confirmed it remains on track to file for U.S. regulatory approval of its Optejet user-filled device in September, which could unlock new commercial channels. Financially, Eyenovia <a href="https://www.benzinga.com/pressreleases/25/05/g45507443/eyenovia-provides-updates-on-potential-merger-with-betaliq-and-development-of-the-optejet-user-fil">reported</a> a narrower first-quarter net loss of $3.5 million, or $1.59 per share, down from $10.9 million, or $18.75 per share, a year earlier. 
Operating expenses fell 70% year-over-year following a broad restructuring initiative and a new debt agreement that defers repayments. CEO Michael Rowe said these efforts are designed to strengthen the balance sheet and position the company for value creation through the potential merger and device approval later this year.
Read Also: <a href="https://www.benzinga.com/25/05/45516277/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-with-over-4-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks With Over 4% Dividend Yields</a>
<h2 class="wp-block-heading">How To Buy EYEN Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Eyenovia&#8217;s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, EYEN has a 52-week high of $124.80 and a 52-week low of $0.85.

EYEN

Eyenovia (EYEN) Shares Explode On Betaliq Merger Progress, Strong Q1 Financials

Raymond James analyst John Freeman maintains EOG Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>) with a Strong Buy and raises the price target from $140 to $148.

Raymond James Maintains Strong Buy on EOG Resources, Raises Price Target to $148

Press Releases

10x Genomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025

Chan Zuckerberg Initiative Launches Billion Cells Project with 10x Genomics and Ultima Genomics to Advance AI in Biology

Earnings

10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025

10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference

10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis

10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products

10x Genomics to Report First Quarter 2025 Financial Results on May 8, 2025

10x Genomics to Participate in the BofA Securities 2025 Healthcare Conference

10x Genomics Reports First Quarter 2025 Financial Results

10x Genomics Announces Patent Litigation Settlement Agreement with Bruker

Agilent Technologies

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

10x Genomics

10x Genomics (TXG) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO